Loading
Biomarkers / Immunotherapy · Journal article
Journal of Translational Autoimmunity · August 20, 2026
A consensus or society position rather than new primary data.
This narrative review reframes osteoarthritis as an immune-dysregulated, heterogeneous whole-joint disease and argues that approved disease-modifying therapies remain absent because current interventions are unstratified and fail to account for distinct immunopathological endotypes. The authors propose that reliable, biomarker-guided patient stratification is necessary to translate preclinical immune-modulatory approaches into effective precision medicine strategies.
Journal article. Osteoarthritis patients globally; emphasis on early disease stages where intervention may modify disease trajectory; recognition of biological heterogeneity across patient populations..
OA affects over 500 million individuals worldwide with annual economic burden exceeding 300 billion dollars Synovial macrophage accumulation correlates with pain severity and radiographic progression in a substantial proportion of patients Synovial fluid profiling consistently demonstrates enrichment of pro-inflammatory cytokines including IL-1β, TNF-α, IL-6, IL-17, and IL-8
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
Clinicians and researchers should recognize that OA is not a uniform disease and that current unstratified therapeutic approaches have failed to yield disease modification. This review supports the concept that precision medicine approaches using biomarker-guided patient stratification will be necessary to advance beyond symptomatic management to genuine disease modification.
A peer-reviewed narrative review synthesizing mechanistic evidence and therapeutic literature to propose a framework for biomarker-guided stratification in osteoarthritis, without reporting original experimental or clinical trial data.
Quoted from the source exactly as published.
Clinicians and researchers should recognize that OA is not a uniform disease and that current unstratified therapeutic approaches have failed to yield disease modification. This review supports the concept that precision medicine approaches using biomarker-guided patient stratification will be necessary to advance beyond symptomatic management to genuine disease modification.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Osteoarthritis (OA) is increasingly recognized as a heterogeneous, immune-modulated joint disease in which chronic low-grade synovial inflammation contributes to structural degeneration and pain, challenging its historical classification as a purely mechanical disorder. Central to this paradigm shift is the recognition that synovial immune activation, particularly macrophage-driven inflammatory programs, is a key axis linking tissue damage to nociception and interacting with complementary inflammatory networks that collectively shape disease progression. However, translating these mechanistic insights into effective disease-modifying therapies has remained limited, with biologics targeting individual inflammatory mediators yielding inconsistent clinical benefit, thereby exposing a fundamental disconnect between molecular stratification and therapeutic response. This disconnect reflects the pronounced biological heterogeneity of OA, in which inflammatory activity is neither uniform nor temporally stable across disease stages. Emerging evidence supports the existence of distinct immunopathological endotypes, yet current therapeutic strategies remain largely unstratified and fail to account for this variability. Parallel advances in synovial biology and systems-level profiling have expanded the conceptual framework beyond single-cell pathways to encompass integrated immune-stromal interactions, but these insights have not yet translated into robust clinical decision-support tools. Therapeutically, multiple immune-modulatory approaches, including macrophage reprogramming, broader pathway modulation, and cellular or senescence-targeting strategies, have shown preclinical promise but remain constrained by limited clinical validation and inadequate patient selection frameworks. Across these approaches, a consistent barrier is the lack of reliable, reproducible biomarkers that link immunological heterogeneity to clinically actionable stratification. This review synthesizes current understanding of immune-driven mechanisms in OA, evaluates the translational performance of immunomodulatory interventions, and critically examines the limitations of existing biomarker strategies. It highlights the need for an integrated framework that links synovial immunobiology to endotype-specific patient classification, arguing that biomarker-guided stratification is a prerequisite for achieving precision immunomodulation and meaningful disease modification in OA.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.